Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

(2014) R. J. Fox et al.   NEUROLOGY

Switching from natalizumab to fingolimod: an observational study

(2013) A. P. Sempere et al.   ACTA NEUROLOGICA SCANDINAVICA

Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab

(2012) S. Rossi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findings

(2012) F Rinaldi et al.   Multiple Sclerosis Journal

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

(2012) Per Soelberg Sørensen et al.   Multiple Sclerosis Journal

Severe relapses under fingolimod treatment prescribed after natalizumab

(2012) D. Centonze et al.   NEUROLOGY

Lethal multiple sclerosis relapse after natalizumab withdrawal

(2012) V. Rigau et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis

(2011) M. A. Sahraian et al.   EUROPEAN JOURNAL OF NEUROLOGY

Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study

(2011) G. Borriello et al.   EUROPEAN JOURNAL OF NEUROLOGY

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study

(2011) María José Magraner et al.   JOURNAL OF NEUROLOGY

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate

(2011) Joachim Havla et al.   JOURNAL OF NEUROLOGY

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

(2011) A. Kerbrat et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

(2011) Ludwig Kappos et al.   LANCET NEUROLOGY

Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?

(2011) K. Hellwig et al.   NEUROLOGY

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated

(2010) Joep Killestein et al.   ANNALS OF NEUROLOGY

Natalizumab dosage suspension: Are we helping or hurting?

(2010) Timothy W. West et al.   ANNALS OF NEUROLOGY

Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy

(2010) Augusto Miravalle et al.   ARCHIVES OF NEUROLOGY

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis

(2010) S. Belachew et al.   EUROPEAN JOURNAL OF NEUROLOGY

Course of relapsing–remitting multiple sclerosis before, during and after natalizumab

(2010) Michael D Kaufman et al.   Multiple Sclerosis Journal

Observations during an elective interruption of natalizumab treatment: a post-marketing study

(2010) Giovanna Borriello et al.   Multiple Sclerosis Journal

IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER WITHDRAWAL OF NATALIZUMAB?

(2010) T. Lenhard et al.   NEUROLOGY

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries

(2009) N. Putzki et al.   EUROPEAN JOURNAL OF NEUROLOGY

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

(2009) M. Hutchinson et al.   JOURNAL OF NEUROLOGY

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

(2008) O. Stuve et al.   NEUROLOGY